Program Guidelines for the National Cancer Institute (NCI) Early Career Cancer Clinical Investigator Award (ECIA) P30 Administrative Supplement for Fiscal Year (FY) 2024 - Formerly the Cancer Clinical Investigator Team Leadership Award (CCITLA)

CONTENTS

Key Dates ........................................................................................................................................2
Award Information ........................................................................................................................2
Funds Available and Allowable Costs .........................................................................................3
Nomination ..................................................................................................................................4
Number of Applications ..............................................................................................................4
Eligibility Criteria for Institutions .............................................................................................4
Eligibility Criteria for Clinical Investigator Candidates .............................................................4
Tips for Applicants .......................................................................................................................6
Application ................................................................................................................................7
Letter of Intent to Apply .............................................................................................................10
Reporting Requirements ...........................................................................................................11
Review Criteria ..........................................................................................................................12
NCI Contact Information ..........................................................................................................14
Appendix A. Instructions and Template for Clinical Trials Table ..............................................15
Key Dates

Letter of Intent (LOI) Due Date: November 6, 2023

Application Due Date: by 5:00 PM local time of applicant organization on December 18, 2023

Earliest Start Date: March 2024 for P30 Cancer Center Support Grants (CCSGs) with start dates of January through March. For P30 CCSGs with start dates of April through September, the anticipated start date is the 2024 start date of the parent P30 CCSG.

Award Information

The Early Career Cancer Clinical Investigator Award (ECIA) recognizes and supports outstanding early career clinical investigators who demonstrate a commitment to becoming an academic clinical researcher and supporting their cancer center’s NCI-funded clinical trials enterprise. The ECIA is designed to promote the retention of early career investigators who wish to initiate a career path that focuses on interventional cancer clinical trials and academic clinical research. The award provides salary support to individuals who do not have independent research grant funding as a Principal Investigator.

A candidate for the ECIA must be nominated by the Cancer Center Director. An ideal candidate must demonstrate a commitment to an academic clinical research career. An identified interest and intent to serve on institutional clinical trial committees, NCI clinical trial networks (NCI National Clinical Trials Network (NCTN), NCI Community Oncology Research Program (NCORP), Experimental Therapeutics Clinical Trials Network (ETCTN), and Cancer Immunotherapy Trials Network (CITN) and other NCI clinical trial-related activities is strongly encouraged. The candidate should demonstrate continued training in academic clinical research, signaling a commitment to academic clinical medicine.

A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to groups that receive one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes (https://grants.nih.gov/policy/clinical-trials/definition.htm). Clinical trials test new methods of screening, prevention, diagnosis, or treatment of a disease.

An intervention is defined as a treatment, procedure, or other action taken to prevent or treat disease, or improve health in other ways. Interventions include drugs, vaccines, medical procedures (such as radiation therapy and surgery), medical devices, behavior changes (such as diet and exercise), education programs, and counseling.
Funds Available and Allowable Costs

The NCI intends to provide partial salary support for clinical investigators at up to 10 NCI-designated Cancer Centers through administrative supplements to P30 CCSGs. The total supplemental budget should not exceed $60,000 (total costs) per year for a total of two years, including salary, fringe benefits and associated facilities and administrative costs.

The candidate must devote at least 15% (1.8 calendar months) effort to the activities associated with this award and the sponsoring institution must protect the awardee’s time for these activities. Although cost sharing is not required, institutions are encouraged to cost share if needed to attain greater than 15% effort for the candidate.

All awards are subject to the terms and conditions of the CCSG notice of grant award and cost principles and other considerations described in the NIH Grants Policy Statement (http://grants.nih.gov/grants/policy/nihgps/index.htm).

Support provided under this supplemental award is not transferable to another investigator or institution.

Allowable costs are limited to:

- Salary (for candidate only), fringe benefits, and associated facilities and administrative costs.
- Travel (up to $2,500/year) and registration fees (up to $2,500/year) (for candidate only) to attend courses, seminars, meetings, conferences, and workshops that support the intent of this award. In the budget justification, include the destination, dates, and duration of stay for all anticipated travel. It is important to clearly state how the travel directly relates to the intent of this award.

Funds from this award may not be used for:

- Research-related costs, including but not limited to research supplies, computers, equipment, core facility fees, or sample or data analysis,
- Salary for personnel other than the candidate,
- Secretarial or administrative assistance and supplies.

Questions about allowable costs should be directed to the NCI Coordinating Center for Clinical Trials (CCCT) ECIA program at NCIECIA@mail.nih.gov.
Nomination

The candidate must be nominated by the Cancer Center Director (Principal Investigator (PI) of the P30 CCSG) based on the candidate’s qualifications, interest and involvement in NCI-funded clinical trials and NCI-funded clinical trials networks (NCTN, NCORP, ETCTN, CITN, etc.), accomplishments, motivation, and plans to pursue a career in academic clinical research. Individuals who have previously received NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA) may not be nominated. For a list of past CCITLA awardees, please refer to: https://www.cancer.gov/about-nci/organization/ccct/funding/ccitla/award-recipients-list.

Number of Applications

Each eligible NCI-designated Cancer Center may submit only one application.

Eligibility Criteria for Institutions

- Only NCI-designated Cancer Centers participating in NCI-funded clinical trials are eligible to apply for this supplement.

Not Eligible:

- Past recipients of NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA).
- Cancer Centers which will enter an extension year during the fiscal year in which this award will be made (FY 2024) are not eligible to apply for the FY 2024 supplement. New administrative supplements cannot be paid to grants in an extension year.

Eligibility Criteria for Clinical Investigator Candidates

All criteria must be met at the time of the application submission deadline (December 18, 2023) to be considered for the award.

- The candidate must be one of the following:
  - Physician (e.g., M.D., D.O.), board certified or have equivalent training and qualifications in specialty area, e.g., medical oncology, radiation oncology, surgical oncology, gynecologic oncology, or equivalent
  - Oncology nurse or clinical psychologist (or similarly qualified clinician) with a doctoral degree
- The candidate must currently be practicing in the oncology clinical setting.
- The candidate must be a full-time faculty member, eligible for promotion, and at least two years post last clinical fellowship and no more than six years from initial academic appointment at the time of the application submission deadline of December 18, 2023 (including appointments held at other institutes).

- The candidate must be engaged in some aspect of the conduct of NCI-funded cancer clinical trials at an academic medical center.

- The candidate must have potential for leadership of the Cancer Center’s clinical trials infrastructure activities. Involvement in the cancer center clinical trial-related activities (e.g., protocol review committees, Institutional Review Board (IRB), etc.) is encouraged but not required at the time of the award; however, it is expected that ECIA recipients will be appointed to at least one of these committees during the award period.

- The candidate must be a United States (US) citizen or noncitizen national of the US possessing a US passport that delineates and certifies status as a national but not a citizen of the US or have been lawfully admitted for permanent residence and possess a currently valid Permanent Resident Card (USCIS Form I-551) or other legal verification of such status.

- The candidate should demonstrate continued training in academic clinical research, signaling a commitment to academic clinical medicine. Training can involve specific courses either at an intuition or national level and/or working with mentors.

- Involvement in NCI clinical trial networks (NCTN, NCORP, ETCTN, CITN, etc.) and or NCI Scientific Steering Committee/Task Force activities is encouraged but not required at the time of the award; however, it is expected that the ECIA recipients will be involved in at least one of these activities during the award period. For additional details on these programs please see the following URLs: https://www.cancer.gov/research/infrastructure/clinical-trials; https://www.cancer.gov/about-nci/organization/ccct/steering-committees.

- Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

- The candidate cannot have been a past recipient of NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA). This applies to the candidate only, and not to the Cancer Center.

- The candidate cannot have been a recipient of NCI R50 Research Specialist (Clinician Scientist) Award.
• The candidate may **not currently be or previously have been**:
  o **A Principal Investigator (PI) of a National Institutes of Health (NIH) peer-reviewed research grant of at least $125,000 in direct costs per year for a minimum of 3 years, with the exception of** mentored career development awards or awards where the PI is required to be mentored by another investigator.
    ▪ Individuals who are currently supported by NIH Mentored Career Development (K) Awards are eligible to be nominated for the ECIA if the support period for the K grant will end by the date when the ECIA award will be made (approximately March 2024 for centers with annual P30 CCSG start dates in January through March; for centers with P30 CCSG start dates in April – September, the ECIA is awarded on the start date). The ECIA is an administrative supplement and not a research grant, and therefore cannot replace effort on a K award.
  o **A project leader or co-leader on an NIH competing multi-component research or center grant or cooperative agreement within a P or U series grant** (e.g., P01 Program Project Grant, U01 or U19 Research Program Cooperative Agreement, P50 Specialized Center Grant).
  o **A PI of a peer-reviewed research grant of at least $125,000 in direct costs per year for a minimum of 3 years from any of the organizations listed in the Organizations with Peer Review Funding Systems at:** https://cancercenters.cancer.gov/PoliciesResources/PoliciesResources.
• **Recipients of ASCO Career Development Awards or mentored career development awards/grants from other organizations ARE eligible and may be nominated for this award.**

Questions about eligibility should be directed to the NCI CCCT ECIA program at NCIECIA@mail.nih.gov.

**Tips for Applicants**

• The application should clearly show the candidate’s planned involvement in their Cancer Center’s NCI-funded clinical trials activities and NCI clinical trial networks.
• The application should clearly show evidence of continued training in academic clinical research, signaling a commitment to academic clinical medicine. Training can involve specific courses either at an institutional or national level and/or working with mentors.
• The application should clearly show the candidate’s planned involvement in NCI clinical trial networks (NCTN, NCORP, ETCTN, CITN, etc.).
• The application should convey the candidate’s planned role in their cancer center’s NCI-funded clinical trials activities.

• The application should highlight how this award would permit the candidate to expand current activities and/or develop/engage in new activities related to promoting successful clinical trials.

• The application should address the review criteria in the announcement.

Application

Applications must be submitted electronically via eRA Commons to the parent award (P30) using PA-20-272 “Administrative Supplements to Existing Grants and Cooperative Agreements (Parent Admin Supplement)” on or before December 18, 2023. Your submission should follow the instructions in the funding opportunity announcement, including the following:

SF424(R&R) Other Project Information

• All instructions in the SF424 (R&R) Application Guide must be followed.

• Other Attachment: include a Clinical Trials Table. Please refer to Appendix A. Instructions and Temple for Clinical Trials Table.

SF424(R&R) Senior/Key Person Profile

• **Biographical Sketch and Research Support:** A biographical sketch of the candidate. The Biographical Sketch Format Page is available at [http://grants.nih.gov/grants/forms/biosketch.htm](http://grants.nih.gov/grants/forms/biosketch.htm).

• In Research Support, list all ongoing, completed, and pending research projects (Federally or non-Federally supported), including the grant number, name of the grant PI, start and end dates of support, funding amount of the grant, title of the grant, goal of the study and **the role of the ECIA candidate in the project** (e.g., Principal Investigator/co-Principal Investigator, co-Investigator). For any NIH P and U series grants, indicate that the candidate is/was not a project leader or co-leader of a research project within the grant.

R&R Budget

Requests are permitted for two years of support only. Allowable costs as listed above in this document.

PHS 398 Research Plan

**Specific Aims:** DO NOT use. Specific Aims are not allowed.

Program Guidelines for the FY 2024 Early Career Cancer Clinical Investigator Award (ECIA)
Research Strategy: must include two parts:

1. Qualifications and Career Plan: Please address the following (no more than six pages):
   
i. **Suitability:** Describe how the candidate meets the intent of the ECIA.
   
   ii. **Training:** Describe specific aspects of the candidate’s training which support an early career cancer investigator role in oncology clinical trials and any training activities anticipated during the time of the award including activities with clinical trials mentors.
   
   iii. **NCI-Funded Clinical Trials:** Describe the candidate’s current, if any, and future planned involvement in NCI-funded clinical trials.
   
   iv. **NCI Trial Network(s):** Describe the candidate’s current roles, if any, and future planned participation in NCI trial networks, including but not limited to, the NCTN, NCORP, ETCTN and CITN and in other NCI clinical trial-related activities, e.g., NCI Scientific Steering Committees (SSCs)/Task Forces (TFs).
   
   v. **Cancer Center Committee(s):** Describe the candidate’s current role(s) and future planned role(s) in cancer center committees such as the IRB, Data Safety Monitoring Board (DSMB), Protocol Review and Monitoring Committee (PRMC) and scientific review committees.
   
   vi. **Clinical Trial-Related Activities:** Describe the candidate’s current and future planned clinical trial-related activities not described above.
   
   vii. **Career Plan:** Describe the candidate’s plans for a career in academic clinical research and how the institution is supporting the candidate in this plan.

2. Planned Activities (no longer than two pages)

   ECIA activities should support the cancer center’s NCI-funded clinical trials and/or clinical trials infrastructure activities.

   i. **An outline and description of activities planned under this award, including a timeline.** For each planned activity include the objective/expected outcome.
   
   ii. **Describe how the activities planned under this award build upon the experience of the candidate beyond merely a continuation of the regular activities.**
   
   iii. **Describe the candidate’s planned future collaborative team experience within division/department, across the institution, with individuals at other institutions and/or with outside organizations.**
   
   iv. **Describe how the candidate’s regular workload will be adjusted to allow sufficient time to dedicate to the proposed ECIA activities.**
v. Describe the activities planned with current mentor(s), if any, under this award and how the planned activities build upon the clinical trial experience of the candidate.

The ECIA can support multiple projects/activities as time, effort, and resources allow. Examples of projects and activities considered appropriate to this award include, but are not limited to (Note: projects/activities listed below are not ordered by priority):

- Designing and implementing initiatives to improve/expand awareness of efficiency of and/or accrual to NCI-funded clinical trials.
- Working with mentor(s) in clinical trials related activities both within their Institution and within NCI clinical trials networks (NCTN, NCORP, ETCTN, CITN, etc.).
- Participating on a cancer center committee (e.g., Institutional Review Board (IRB)) that enhances the awardee's clinical trials knowledge or leadership.
- Participating in NCI clinical trial network (NCTN, NCORP, ETCTN, CITN, etc.) committees.
- Participating in NCI clinical trial committees such as Scientific Steering Committees and/or Task Forces.

Letters of Support

A cover letter and three signed letters of support on behalf of an individual's application must be submitted with the application.

Cover Letter (1 page) signed by the PI of the P30 CCSG: A cover letter, signed by the PI of the P30 CCSG, must accompany each application and should only include:

- the title of this funding opportunity
- that the center is applying for this administrative supplement
- the name and email address of the candidate and of the administrative official for the application
- a statement verifying that the candidate meets all eligibility criteria of the award
- the process used to select the candidate

Three Letters of Support

- One of the letters of support must be provided by the Cancer Center Director and should be appended to the application with the other letters of support, rather than included in the cover letter.

Program Guidelines for the FY 2024 Early Career Cancer Clinical Investigator Award (ECIA)
At least one of the letters of support should be an institutional support letter from the Department Chair or appropriate institutional official that indicates:

- A description of the academic status of the applicant and any additional support provided by the institution.
- A clear level of commitment by the institution to developing the candidate’s career as an academic clinical investigator.
- The extent to which the candidate will have dedicated time for activities proposed in the application. This letter must demonstrate a commitment to allow at least 15% (1.8 calendar months) effort for activities proposed in the application.
- How the institution intends to continue to provide or augment its support for the candidate’s clinical research efforts beyond the award performance period.

At least one of the letters of support should be from a mentor (institutional or NCI clinical trials enterprise (NCTN, NCORP, ETCTN, CITN, etc.) that indicates:

- A description of the current and planned clinical trials activities of the applicant.
- A clear level of commitment by the mentor to developing the candidate’s career as an NCI clinical trial investigator.
- The extent to which the mentor is engaged with the applicant in clinical trials activities proposed in the application.

NOTE: ECIA does not provide direct support for research. Therefore, “PHS Human Subjects and Clinical Trials Information” forms are not required.

Letter of Intent to Apply

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NCI staff to estimate the potential review workload and plan the review.

Prospective cancer center applicants are asked to submit a letter of intent that includes the following information:

- Title of this funding opportunity
- Intent to apply for this administrative supplement
- Name of the cancer center and Center Director (PI of the P30 CCSG)
- Not required, but please include if known:
  - The name and email address of the Candidate
The names and institutional affiliations of the two individuals other than the Center Director who will provide letters of support for the application.

The Letter of Intent should be provided by email no later than November 6, 2023 to:

ECIA Program
Coordinating Center for Clinical Trials
National Cancer Institute
NCIECIA@mail.nih.gov

Molly Maher
Office of Cancer Centers
National Cancer Institute
molly.maher@nih.gov

Additionally, please notify both contacts listed below by email at the time of submission of your application to eRA Commons. Do not attach the application to the email.

ECIA Program
Coordinating Center for Clinical Trials
National Cancer Institute
NCIECIA@mail.nih.gov

Molly Maher
Office of Cancer Centers
National Cancer Institute
molly.maher@nih.gov

Reporting Requirements

A progress report for the ECIA supplement must be included as a separately labeled section in the annual progress report for the CCSG for any reporting period for which ECIA supplemental funds are received.

The progress report should include:

- Details on the progress and outcome of each activity/project listed in the application.
- Awards and honors received during the performance period related to activities under this award.
- Changes in academic rank or track during the performance period of this award.
- Publications, journal articles, and patents related to this award.
- Impact to date of the award on the candidate’s career development.
- Opportunities that otherwise would not have been possible without the award.
- Value added by the award (e.g., for the institution or other staff).
Publications resulting from this award should acknowledge the funding source as follows: “This study was supported in whole or in part by funding from the Early Career Cancer Clinical Investigator Award awarded by the National Cancer Institute Coordinating Center for Clinical Trials (CCCT) though a supplement to P30 xxxxxxx.”

Publications, journal articles and/or patents produced under an NIH award-supported project must bear an acknowledgment and disclaimer, as appropriate, as provided in NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards Section 8.2 “Administrative Requirements—Availability of Research Results: Publications, Intellectual Property Rights and Sharing Research Resources.”

Review Criteria

There is no predetermined weighting for the categories of review criteria. Bulleted items in each category serve as examples for addressing review criteria. An application does not need to be strong in all areas to receive a meritorious assessment.

Suitability

- Does the candidate meet the intent of the award?
  - Active interest in engaging in NCI-funded clinical trials as shown by planned activities
  - Willingness to play a critical role in the cancer center's NCI-funded clinical trials infrastructure activities as shown by planned activities
  - Record of service in institutional clinical trial-related activities
  - Record of service on NCI clinical trials enterprise (NCTN, NCORP, ECTCN, CITN, etc.) committees and/or NCI Scientific Steering Committees or Task Forces.

Training

- Does the candidate have training and experience strongly supporting a role in oncology clinical trials?
- Is the applicant involved in any current training activities either through course work or with a mentor(s)?
- Are the planned training activities either through course work or with a mentor(s) clearly delineated in the application?
Experience, current and future planned activities clinical trial-related activities

- To what extent has the candidate proposed future planned activities in **NCI-funded** clinical trials such as those funded through the Division of Cancer Treatment and Diagnosis (DCTD), Division of Cancer Prevention (DCP), Division of Cancer Control and Population Sciences (DCCPS), Office of the Director (OD), or NCI-designated Cancer Centers?
- To what extent does the candidate have or plan to have roles in clinical trial-related activities both at the institutional and national level?
- To what extent does the candidate work with mentors in support of clinical trial activities or have plans to work with mentors in support of clinical trial activities?

Candidate’s planned activities

- Do the proposed activities meet the intent of the award? ECIA activities should be in support of the cancer center’s NCI-funded clinical trials and/or clinical trials infrastructure activities.
- Are the proposed activities new and/or an **expansion** of regular activities rather than a continuation of regular activities?
- Do the planned activities build upon the experience of the candidate beyond merely a continuation of the regular activities?
- Do the proposed activities benefit from unique features of the scientific environment, subject populations, or employ useful collaborative arrangements?
- Will this award allow the candidate to develop/engage in new activities related to clinical trials at his/her institution that would not likely happen without this award?
- Does the application indicate appropriate commitment of time and effort for the proposed activities?

Institutional commitment to support the candidate’s planned activities and career in clinical research

- Is there clear commitment of the institution to relieve the candidate of sufficient duties to allow at least 15% (1.8 calendar months) effort for activities proposed in the application?
- Is the level of institutional commitment to the career development of the candidate appropriate to be considered for this award?
Does the candidate's institution intend to continue to provide or augment its support for the candidate's efforts in NCI-funded clinical trials and clinical trials infrastructure activities beyond the award performance period?

NCI Contact Information

For programmatic questions:

Wolf Lindwasser, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6241
Email: wolf.lindwasser@nih.gov

or

The NCI Program Director assigned to your P30 CCSG.

Questions regarding fiscal and administrative matters should be addressed to the Grants Specialist for your Cancer Center, NCI Office of Grants Administration.
Appendix A. Instructions and Template for Clinical Trials Table

Using the template in this Appendix, list all national, externally-peer reviewed, institutional, and industry clinical trials which the candidate has had a role in the two years prior to the application and which are currently active, closed, approved or under review. **The table must be in the format of the table in this appendix.** Use legal size paper for the table if needed.

**Trial Type:** Sort the trials by type of clinical trial.

- **National:** NCI National Clinical Trials Network (NCTN) and other NIH-supported National Trial Networks

- **Externally Peer-Reviewed:** R01s, SPORES, U01s, U10s, P01s, CTEP, or any other clinical research study mechanism supported by the NIH or an organization listed in the Organizations with Peer Review Funding Systems at: [https://cancercenters.cancer.gov/PoliciesResources/PoliciesResources](https://cancercenters.cancer.gov/PoliciesResources/PoliciesResources).

- **Institutional:** In-house clinical research studies authored or co-authored by cancer center investigators and undergoing scientific peer-review solely by the Protocol Review and Monitoring System of the cancer center. The cancer center investigator has primary responsibility for conceptualizing, designing and implementing the clinical research study and reporting results.

- **Industry:** Clinical research studies supported solely by industry where the investigator has primary responsibility for implementing and accruing.

**NCT ID:** Provide the unique ID assigned to the trial by the National Clinical Trial program (ClinicalTrials.gov) for trials that have been submitted to ClinicalTrials.gov Protocol Registration System (PRS) previously. The ClinicalTrials.gov ID appears as "NCT" followed by 8 numeric characters (such as NCT12345678). In the table, do not include “NCT” in the ID (e.g., for NCT12345678, only list “12345678” in the column). If not applicable, enter “N/A” in this column.

**Other ID(s):** Provide the unique identifier for this trial. Where available, list the common protocol number that the trial is known under nationally, if one exists. For other trials that do not have a common protocol number, use an internal protocol identification or IRB number.

**Candidate’s Role:** The role of the ECIA candidate in the trial (e.g., ‘Overall PI’, ‘Overall Co-PI’, ‘Site PI’, ‘Associate Investigator’, etc.)

**Date Open: Site (activation):** The date the trial opened at your center.

**Date Closed: Site:** The date the trial closed to accrual at your center. This does not include patient follow-up. If the trial is still open, leave this field blank.
Status (as of September 30, 2023): Under Review, Approved, Active, Closed - Not Yet Published, Closed, Enrolling by Invitation, Temporarily Closed to Accrual, Temporarily Closed to Accrual and Intervention, or Temporarily Not Available

Phase: For Intervventional trials acceptable phases include pilot, feasibility, 0, I, II, III, IV, or combinations such as I/II. For trials without phases, indicate “N/A.”

Official Title: Official name of the protocol provided by the trial PI or sponsor (Limit: 8000 characters or fewer).

Multi-Institutional Trial: Indicate if the trial is multi-institutional by inserting ‘Y’ or ‘N’ in the “multi-institutional trial” column.

Multi-Institutional Clinical Trial: Clinical trial that recruits participants from two or more geographically distinct enrollment Institutions not affiliated with your cancer center (e.g., other NCI-designated Cancer Centers or other research institutions). The Institutions are usually distinct in other characteristics (e.g., demographic, socioeconomic, or clinical).

Total Targeted Accrual:

- Entire Trial: For both single-institution and multi-institutional trials initiated at your center, indicate the total number of participants needed for the entire trial. For multi-Institutional trials that your center participates in but did not initiate, leave “Entire Trial” column empty if not known. Do not submit a targeted range, such as “10 – 100.”
- Your Center: For single-institution and multi-institutional trials initiated at your center, indicate the total number of participants your center is expected to accrue for the study. For single-institution trials the “Total Accrual for Your Center” and the “Total Targeted Accrual Entire Trial” numbers will be the same. Do not submit a targeted range, such as “10 – 100.”

Center Accrual: List the number of participants enrolled in the clinical trial at your cancer center, including formal Consortium Partners.

- 12 Months: Provide the number of participants accrued to this clinical trial during the last 12 months.
- To Date: Provide the number of participants accrued to this clinical trial since the trial was opened.

Enrolled on Trial by Candidate: List the number of participants which the candidate has enrolled in the clinical trial.

- 12 Months: Provide the number of participants accrued to this clinical trial during the last 12 months.
• **To Date**: Provide the number of participants accrued to this clinical trial since the trial was opened.
Program Guidelines for the FY 2024 Early Career Cancer Clinical Investigator Award (ECIA)

<table>
<thead>
<tr>
<th>Clinical Trials</th>
<th>Total Targeted Accrual</th>
<th>Center Accrual</th>
<th>Enrolled on Trial by Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trial Type</strong></td>
<td><strong>NCT ID</strong></td>
<td><strong>Other ID(s)</strong></td>
<td><strong>Candidate’s Role</strong></td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
<td>----------------</td>
<td>-------------------</td>
</tr>
</tbody>
</table>

ADD ADDITIONAL ROWS AS NEEDED